Future Prospects for Radiotherapy for Hodgkin Lymphoma

Chapter
First Online:

Abstract

A number of issues are still unresolved regarding the optimal use of radiotherapy in the treatment of Hodgkin lymphoma (HL). With regard to the prognostic parameters used to identify unfavorable patients, there is a disagreement on the precise criteria between different trial groups that need harmonization. Inclusion of newly identified biological markers in the prognostic evaluation of patients is expected. Highly conformal radiotherapy in the combined modality setting is used increasingly, and the issues of the definition of the pre-chemotherapy lymphoma volume on the post-chemotherapy images pose both technical and patient flow coordination challenges. Lower radiation doses are now being documented. The benefit of radiotherapy in the relapse setting is not fully exploited. The use of PET scans to select patients for omission of radiotherapy is still experimental, and results of ongoing randomized trials are awaited. Advances in radiation and imaging technology should be fully implemented to the benefit of HL patients to maintain very high cure rates and minimize treatment-related morbidity.

Keywords

Hodgkin Lymphoma Involved Field Radiation Therapy International Prognostic Score Hodgkin Lymphoma Patient German Hodgkin Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Borchmann P, Diehl V, Goergen H et al (2009) Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 trial. Blood 114: 717Google Scholar
  2. Campbell BA, Voss N, Pickles T et al (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26:5170–5174PubMedCrossRefGoogle Scholar
  3. Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410PubMedCrossRefGoogle Scholar
  4. Engert A, Diehl V, Pluetschow A et al (2009) Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10. Study supported by the Deutsche Krebshilfe and in part by the Competence Network Malignant Lymphoma. Blood 114(22): Abstract 716Google Scholar
  5. Grow A, Quon A, Graves EE et al (2005) Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol 23 (Suppl.):583SGoogle Scholar
  6. Gu X, Pan H, Liang Y et al (2010) Implementation and evaluation of various demons deformable image registration algorithms on a GPU. Phys Med Biol 55:207–219PubMedCrossRefGoogle Scholar
  7. Hutchings M, Berthelsen AK, Jakobsen AL et al (2005) Volume of abnormal tumour tissue on FDG-PET - a predictor of progression-free survival in Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 63:S45Google Scholar
  8. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D et al (2007) Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110:179–185PubMedCrossRefGoogle Scholar
  9. Murphy SB, Morgan ER, Katzenstein HM et al (2003) Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 25:684–687PubMedCrossRefGoogle Scholar
  10. Picardi M, De Renzo A, Pane F et al (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48:1721–1727PubMedCrossRefGoogle Scholar
  11. Specht L (1996) Prognostic factors in Hodgkin’s disease. Semin Radiat Oncol 6:146–161PubMedCrossRefGoogle Scholar
  12. Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362:875–885PubMedCrossRefGoogle Scholar
  13. Yahalom J, Gulati SC, Toia M et al (1993) Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol 11:1062–1070PubMedGoogle Scholar
  14. Yang D, Goddu SM, Lu W et al (2010) Technical note: deformable image registration on partially matched images for radiotherapy applications. Med Phys 37:141–145PubMedCrossRefGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Departments of Oncology and Haematology, Finsen Centre, RigshospitaletThe University of CopenhagenCopenhagenDenmark
  2. 2.Department of Radiation OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations